Individuals with T2D and diabetic nephropathy are at higher risk for adverse cardiovascular events. This study compared patient characteristics and disease burden by severity of albuminuria (normoalbuminuria [NOR], microalbuminuria [MIU], macroalbuminuria [MAU]) among T2D patients tested for albuminuria and initiating new diabetes pharmacotherapy not dispensed in the prior 6 months.
From a U.S. database of linked electronic health records and insurance claims, we identified adults with T2D initiating a new DPP-4, GLP-1, or sulfonylurea between June 2016 and June 2019 (index event), with a lab value for urinary albumin: creatinine ratio (UACR) or albumin excretion rate (AER). Albuminuria was defined as NOR if UACR (in mg/g) or AER (in mg/day) <30, MIU if 30≤UACR/AER≤300, and MAU if 300<UACR/AER<5,000. Baseline characteristics and healthcare resource utilization for 6 months pre-index were compared among cohorts.
Patients with an available UACR/AER value (n=127,405) represented ∼12% of adult T2D therapy initiators. Severity of albuminuria was NOR (54.9%), MIU (37.0%), and MAU (8.1%). As severity increased, the percentage of patients with baseline cardiovascular conditions and medications and with baseline hospitalizations also increased (Table). More research is needed into the unique needs of the T2D with MAU population.
L. Blonde: Advisory Panel; Self; AstraZeneca, Gilead Sciences, Inc. Consultant; Self; Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; Janssen Scientific Affairs, LLC., Novo Nordisk A/S, Sanofi. Speaker’s Bureau; Self; Janssen Pharmaceuticals, Inc., Sanofi. A. Wilk: Employee; Self; Veradigm. A. Bogdanov: None. J. Vasey: None. L. Kallenbach: None. M. Durkin: Employee; Self; Janssen Scientific Affairs, LLC.
Janssen Scientific Affairs, LLC